View Post

Updated recommendations for managing hereditary breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Health Day From: medicalxpress.com One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, according to a rapid recommendation update published by the American Society for Clinical Oncology (ASCO). Following presentation of the results from …

View Post

Olaparib Provides Meaningful Benefit 1 Year After Standard of Care Therapies in BRCA1/2+, High-Risk, Early HER2- Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Courtney Marabella From: onclive.com Olaparib demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone therapy, or radiation therapy, in patients with BRCA1/2-mutant, early HER2-negative breast cancer who are at a high risk for recurrence. Olaparib (Lynparza) demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone …

View Post

Phase 3 OlympiA Trial for HER2-Negative Breast Cancer Moves to Early Primary Analysis Per IDMC Recommendation

In Clinical Studies News by Barbara Jacoby

By: Hannah Slater From: cancernetwork.com In the OlympiA trial, patients with high-risk HER2-negative breast cancer were randomized 1:1 to receive either olaparib or placebo for 12 months. A planned interim analysis found that the phase 3 OlympiA trial (NCT02032823) crossed the superiority boundary for its primary end point of invasive disease-free survival (iDFS) and demonstrated a sustainable, clinically relevant treatment …